This HTML5 document contains 124 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://dx.doi.org/10.1038/
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7https://scigraph.springernature.com/pub.10.1038/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37232854
rdf:type
wikibase:Item
schema:description
vědecký článek vedecký článok wetenschappelijk artikel wissenschaftlicher Artikel наукова стаття, опублікована у вересні 2016 مقالة علمية نشرت في 06 سبتمبر 2016 научни чланак article científic videnskabelig artikel artigo científico vetenskaplig artikel bilimsel makale articolo scientifico article scientifique artículu científicu espublizáu en 2016 scientific article published on 06 September 2016
p:P577
wds:Q37232854-06D140DE-494D-402B-82CC-48743C31E464
wdt:P577
2016-09-06T00:00:00Z
p:P407
wds:Q37232854-2F160439-3E81-4DE4-A599-44B57F3BAB20
wdt:P407
wd:Q1860
p:P2888
wds:Q37232854-A853423D-07FC-4649-9355-330151B6490E
wdt:P2888
n7:srep32946
p:P2860
wds:Q37232854-2D213B49-2C1B-4150-9DA1-087451C46B00 wds:Q37232854-E9A15E93-CC34-41F6-A59C-33E8CCABCA6D wds:Q37232854-EFB39D30-47B5-44DA-996F-2B54F80D6DF9 wds:Q37232854-F9C318A3-AB31-401C-BA5A-43A1FBABC3AB wds:Q37232854-38C609EE-CE2D-4DD5-80A9-FA66F6F9AA11 wds:Q37232854-464EA271-B668-4C6B-A4F1-929EB2F091F5 wds:Q37232854-52EE520A-6BE4-4A51-A8D8-4B564187E9AC wds:Q37232854-5CE73048-564F-4E13-8E7C-4DC6188E47B2 wds:Q37232854-6BB7CF61-75FE-49BC-8BCC-273D246C3158 wds:Q37232854-781CF664-89BE-43E2-8FD9-2830EBAE59D4 wds:Q37232854-837DC963-3A56-4B1B-829C-37AB4413FF24 wds:Q37232854-A2CEBF0B-4584-4F42-95D0-BEFB4AE64F4F wds:Q37232854-ADAE05AD-A230-472B-B1C7-4DAB486804F6 wds:Q37232854-BE972621-55D8-4835-A4A6-86CD950651F8 wds:Q37232854-C7700098-717F-48A3-BF9B-18BA96CA03F8 wds:Q37232854-C923DDC3-3230-45F5-808D-74E900F0F332 wds:Q37232854-CAD447E1-48B8-4211-AAF7-91EFC84EB933 wds:Q37232854-E0052FB3-E9F8-4023-8E07-B22D349E0DA7 wds:Q37232854-045785A4-D8FE-45A7-B8B7-5108AA8F2126 wds:Q37232854-074ED5D8-FB3E-4754-8A05-1F4060453F45 wds:Q37232854-0D1E427C-54F0-4A6E-A76E-8E6A86371F47 wds:Q37232854-0FD9B534-8DC4-476B-A4BD-80B325624F72
wdt:P2860
wd:Q45346796 wd:Q40605097 wd:Q48322695 wd:Q72444174 wd:Q41141076 wd:Q38120906 wd:Q33381094 wd:Q37096391 wd:Q40669483 wd:Q44567674 wd:Q39112711 wd:Q54027653 wd:Q34471062 wd:Q38583290 wd:Q40377715 wd:Q42730898 wd:Q37125036 wd:Q84818442 wd:Q33744498 wd:Q38223840 wd:Q22241238 wd:Q35815669
p:P2093
wds:Q37232854-BC26441A-4742-4BDA-81C9-DD53DCDF772D wds:Q37232854-E5A08E2A-BDBC-4D79-97D2-C0E3FBA8D046 wds:Q37232854-E8827898-8D57-4182-A996-5C65260ACA52 wds:Q37232854-66CBF9A0-BC2C-40CC-B9D2-1A31355F847B wds:Q37232854-ED88AFDA-AED9-4114-B7A4-7DBF8A25E8F3 wds:Q37232854-32B54CC9-5ABA-407C-981E-04A61821EFCC
wdt:P2093
Anja Grah Johannes Pammer Thorsten Fuereder Marie-Bernadette Aretin Hannah Fuchs Doris Posch
rdfs:label
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
skos:prefLabel
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
schema:name
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer. Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
p:P50
wds:Q37232854-331CE966-B56B-4A02-8647-6BD8B618FC07
wdt:P50
wd:Q110415456
p:P1476
wds:Q37232854-2BE3CA57-5440-482C-B092-08760BDEECB2
wdt:P1476
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
p:P304
wds:Q37232854-B236E52F-1C16-4459-B1B5-CCAF37178D61
wdt:P304
32946
p:P31
wds:Q37232854-BEE6D513-5898-4F95-AA55-433EF1C89816
wdt:P31
wd:Q13442814
p:P921
wds:Q37232854-67A535CB-85EF-4A05-85A8-41D283FE802D wds:Q37232854-5D3847C0-A13F-4F5D-AD6E-3EE3F76FCB33 wds:Q37232854-517827A8-D5AD-4864-A8C0-AFBCBC09E9A6 wds:Q37232854-E165D998-3FBC-47C9-BF43-4A5CB68C022D wds:Q37232854-B7955BBA-A873-4BDF-ABCB-A552B5D2F280
wdt:P921
wd:Q18554836 wd:Q420436 wd:Q420296 wd:Q1783924 wd:Q18966654
p:P698
wds:Q37232854-67FFC6D6-F7EC-41E9-8BB7-00CFD98AB6E0
wdtn:P698
n12:27597175
wdt:P698
27597175
p:P1433
wds:Q37232854-8EA9742A-2446-49B5-9A4E-BBD445DE9933
wdt:P1433
wd:Q2261792
p:P478
wds:Q37232854-B04FFAE5-FC86-469E-AE79-88DCD9B18484
wdt:P478
6
p:P356
wds:Q37232854-B904B176-080A-4E81-8762-F9451C632D4F
wdtn:P356
n13:SREP32946
wdt:P356
10.1038/SREP32946
p:P275
wds:Q37232854-a1fee17e-cf93-4303-a119-750640eac0e9
p:P6216
wds:Q37232854-ec8d83a2-56e7-48ab-8eed-74bf28b7ea4e
wdt:P275
wd:Q20007257
wdt:P6216
wd:Q50423863
p:P6179
wds:Q37232854-11F3B3C4-552C-4D9E-8409-5F51FEF5D65D
wdt:P6179
1001459529
p:P932
wds:Q37232854-BEEC5931-F91B-4833-A39A-A111D2AD6915
wdt:P932
5011715